"In addition, the risk of secondary cancers from DNA-repair inhibition needs to be considered carefully if these agents are used for longer periods in healthier patients," Dr. Carey and Dr. Sharpless cautioned.
Dr. O’Shaughnessy reported receiving speaking and consulting fees from Sanofi-Aventis, which recently bought study sponsor Bipar Sciences. One coauthor reported receiving travel support from Sanofi-Aventis and another reported stock ownership. Several coauthors are employees with stock options in the study sponsor Bipar Sciences, which is developing iniparib with its new parent company. Dr. Carey reported no conflicts. Dr. Sharpless reported financial relationships with G-Zero Therapeutics, consultancy for Wyeth, and royalties from Merck.